US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant
Lilly And AstraZeneca Antibodies Retain Potency
The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2.
